共查询到20条相似文献,搜索用时 15 毫秒
1.
Musgrove EA 《Breast cancer research : BCR》2004,6(2):65-68
Recent data have suggested the epidermal-growth-factor receptor (EGFR) as a point of convergence for several different classes of receptor. Civenni and colleagues have now demonstrated crosstalk between Wnt signalling and the EGFR, showing that in breast epithelial cells Wnts activate downstream targets of the EGFR, including cyclin D1. Given the role of members of these pathways in the aetiology of breast cancer and as markers of outcome and potential therapeutic targets in breast cancer, this observation has a number of potential implications important for both the basic biology of breast cancer and the clinical management of the disease. 相似文献
2.
Recent data have suggested the epidermal-growth-factor receptor (EGFR) as a point of convergence for several different classes
of receptor. Civenni and colleagues have now demonstrated crosstalk between Wnt signalling and the EGFR, showing that in breast
epithelial cells Wnts activate downstream targets of the EGFR, including cyclin D1. Given the role of members of these pathways
in the aetiology of breast cancer and as markers of outcome and potential therapeutic targets in breast cancer, this observation
has a number of potential implications important for both the basic biology of breast cancer and the clinical management of
the disease. 相似文献
3.
《European Journal of Cancer Supplements》2003,1(8):29-33
Following the demonstration of encouraging antitumour activity and favourable tolerability by the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in phase I studies, an Expanded Access Programme (EAP) allowed gefitinib to be given to patients with advanced non-small-cell lung cancer (NSCLC) who had exhausted all other treatment options. The EAP case reports presented here demonstrate the remarkable effect that gefitinib can have on individual patients with a range of clinical characteristics, including brain and bone metastases, poor performance status and advanced age. Gefitinib not only shows antitumour activity against primary tumours and metastases, it also leads to meaningful improvements in disease-related symptoms and quality of life for many NSCLC patients. 相似文献
4.
《中华肿瘤杂志》2006,28(11):M0004-M0004
Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous-cell carcinoma (HNSCC) and its expression levels correlate with decreased patient survival. Nonetheless, therapies aiming at blocking EGFR has shown limited efficacy in a proportion of patients with HNSCC in clinical trials. Sok et al. in a recent paper (Clin Cancer Res, 2006, 12:5064-5073 ) attempted to ascertain whether it is due to mutation of EGFR. As the most common form of mutation of EGFR seen in several other types of cancer is a truncation mutation, EGFR 相似文献
5.
Epidermal growth factor receptor (EGFR) is highly expressed in triple-negative breast cancer (TNBC), and elevated levels correlate with poor prognosis. In analogy with the paradigm of oncogene addiction, blocking EGFR in TNBC was expected to have clinical efficacy – but this has not been the case. Reasons for these results have remained elusive. Recently, Meyer and colleagues showed interplay between EGFR and the epithelial-to-mesenchymal transition-associated AXL receptor in TNBC cells, which might provide some clues. 相似文献
6.
7.
8.
9.
10.
Roviello Giandomenico Aprile Giuseppe D’Angelo Alberto Iannone Luigi Francesco Roviello Franco Polom Karol Mini Enrico Catalano Martina 《Gastric cancer》2021,24(4):765-779
Gastric Cancer - Gastric cancer is one of the most common malignancy worldwide. In unresectable or metastatic disease, the prognosis is poor and in generally less than a year. HER2 expression... 相似文献
11.
Interaction of transforming growth factor-β (TGF-β) and epidermal growth factor (EGF) in human glioma cells 总被引:6,自引:0,他引:6
Held-Feindt J Lütjohann B Ungefroren H Mehdorn HM Mentlein R 《Journal of neuro-oncology》2003,63(2):117-127
Gliomas are characterized by a deregulation of growth factor production and growth factor receptors expression, e.g. overproduction of the cytokine transforming growth factor- (TGF-) and overexpression/constitutive activation of receptors for the epidermal growth factor (EGF). Potential interactions of such growth factors and their signaling cascades could enhance the malignancy of these tumors. Therefore, we investigated the effects of TGF- and EGF alone and in combination on the proliferation of glioma cells cultivated from eight solid human WHO grade IV gliomas and one glioma cell line, analyzed the expression and intactness of the TGF--signaling molecules Samd-4 and -2, and the phosphorylation of the EGF-signaling kinases ERK 1/2. The effects were divergent and complex: Whereas EGF mostly stimulated glioma cell proliferation, TGF- either enhanced, inhibited or had no significant effect on proliferation. In combination, co-stimulation and inhibition of the EGF-induced mitogenic activity could be observed. Smad-4/-2 were expressed in all glioma cells, one point mutation at base 1595 in Smad-4 did not affect its protein sequence. In part of the glioma cells, reduced phosphorylation of ERK 1/2 and expression of cyclin-dependent kinase inhibitor 1 or p21 was observed in co-stimulation experiments. These experiments show that TGF- can inhibit EGF-mediated effects only in some gliomas, whereas it enhances it in others. The interaction of both factors is very complex and varies between different gliomas. 相似文献
12.
The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant pleural mesothelioma samples and therefore may be a potential therapeutic target. Targeted EGFR therapy has been successful in non-small cell lung cancer using small molecule tyrosine kinase inhibitors and in colorectal cancer using monoclonal anti-EGFR antibodies. However, phase II clinical trials based on EGFR tyrosine kinase inhibitor therapy have so far not shown promise in mesothelioma. This review includes a background to targeted EGFR treatment strategies, explores putative therapy resistance mechanisms, including the role of predictive biomarkers, and describes the current status of targeted EGFR therapeutic strategies for mesothelioma patients. 相似文献
13.
14.
《European Journal of Cancer Supplements》2003,1(8):17-22
In recent years it has become widely recognised that clinical benefit in cancer patients depends on factors such as symptom improvement, symptom-free survival and low toxicity, as well as the more conventional measures of tumour regression and improved overall survival. Advanced non-small-cell lung cancer (NSCLC) is a debilitating disease, the prognosis for which has improved very little over the past few decades. There is therefore a clear need for alternative options for the treatment of advanced NSCLC. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) has been in used in clinical trials for several years. The clinical benefit it provides in patients with advanced NSCLC is a product of the notable antitumour activity, high rates of symptom improvement and favourable tolerability profile. 相似文献
15.
Roggero E Busi G Giancarla B Palumbo A Antonella P Pedrazzini A Augusto P 《Journal of neuro-oncology》2005,71(3):277-280
This report highlights the case of a symptomatic 77-year-old non-smoking female patient who was diagnosed with advanced non-small-cell
lung cancer (NSCLC), metastatic to the liver and contralateral lung. After tumor progression in the liver and lung following
polychemotherapy, multiple diffuse brain and cerebellar metastases were apparent. Oral treatment with the epidermal growth
factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’) 250 mg/day resulted in progressive and durable symptom relief,
and improvements in quality of life and performance status. Reductions in the size of the primary pulmonary tumor and brain,
cerebellar, and liver metastases were observed. Furthermore, gefitinib was well tolerated with an absence of adverse events.
These results provide evidence that oral gefitinib is active in patients with advanced NSCLC and central nervous system metastases.
An erratum to this article is available at . 相似文献
16.
Are DNA ploidy and epidermal growth factor receptor prognostic factors for untreated ovarian cancer? A prospective study 总被引:1,自引:0,他引:1
Nagai N Oshita T Fujii T Katsube Y Matsubayashi S Ohama K 《American journal of clinical oncology》2001,24(3):215-221
To identify prognostic factors for untreated ovarian cancer, DNA ploidy, proliferative index (P.I.) and epidermal growth factor receptor (EGFR) expression were analyzed in a prospective series of 40 patients with ovarian cancer and 7 patients with borderline malignant ovarian tumor followed up for 5 years or more (median, 77 months). The frequency of aneuploid cells was 53.8% (21/39) in ovarian cancer and 14.3% (1/7) in borderline malignancy. There was no significant association between DNA ploidy and the clinicopathologic findings, in which aneuploid ovarian cancer was more common among advanced tumors. The S-phase fraction and P.I. value were higher in the patients with aneuploid tumors (p = 0.076). EGFR expression was detected in 76.9% (30/39) of ovarian cancers and 42.9% (3/7) of borderline malignant ovarian tumors, and the mean EGFR level was 5.8 +/- 12.1 (range: 0-49.5) and 28.3 +/- 71.1 (range: 0-189.4) fmol/mg protein, respectively. There was no correlation between EGFR expression and DNA ploidy, P.I., and clinicopathologic findings analyzed. The 5-year survival rate in patients with aneuploid tumors was significantly worse in patients with ovarian cancer (p = 0.0165, log-rank test). No significant relationship was shown between P.I., EGFR expression, and 5-year survival. Cox multivariate analysis showed that DNA ploidy, P.I., and EGFR expression are not associated with the risk of death (p = 0.5917, p = 0.9924, and p = 0.6840, respectively), although clinical stage shows a significant relationship (p = 0.0027). Our data showed that DNA ploidy is significantly related to the prognosis by univariate analysis, but DNA ploidy, P.I., and EGFR expression were not independent prognostic factors for the untreated ovarian cancer. 相似文献
17.
Aberrations in the signaling cascade of the epidermal growth factor receptor are common to several solid tumors. Compounds aimed at targeting this pathway have been approved for use by the US Food and Drug Administration for lung, head and neck, pancreas, and colorectal carcinomas. Unfortunately, only the minority of patients treated with this class of agents will have responses or improvements in survival. This article reviews the data on agents that exploit tumor dependency on epidermal growth factor receptor cascade and describes the knowledge on how to discern the appropriate patient population for receiving these agents. 相似文献
18.
Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
下载免费PDF全文
![点击此处可从《Cancer science》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Eri Banno Yosuke Togashi Yu Nakamura Masato Chiba Yoshihisa Kobayashi Hidetoshi Hayashi Masato Terashima Marco A. de Velasco Kazuko Sakai Yoshihiko Fujita Tetsuya Mitsudomi Kazuto Nishio 《Cancer science》2016,107(8):1134-1140
Most patients with non‐small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations, such as deletions in exon 19 or the L858R mutation in exon 21, respond dramatically to EGFR tyrosine kinase inhibitors (EGFR‐TKI), and their sensitivities to various EGFR‐TKI have been well characterized. Our previous article showed the in vitro sensitivities of EGFR exon 18 mutations to EGFR‐TKI, but little information regarding the sensitivities of other uncommon EGFR mutations is available. First, stable transfectant Ba/F3 cell lines harboring EGFR L858R (Ba/F3‐L858R), L861Q (Ba/F3‐L861Q) or S768I (Ba/F3‐S768I) mutations were created and their drug sensitivities to various EGFR‐TKI were examined. Both the Ba/F3‐L861Q and Ba/F3‐S768I cell lines were less sensitive to erlotinib, compared with the Ba/F3‐L858R cell line, but their sensitivities to afatinib were similar to that of the Ba/F3‐L858R cell line. The Ba/F3‐L861Q cell line was similarly sensitive and the Ba/F3‐S768I cell line was less sensitive to osimertinib, compared with the Ba/F3‐L858R cell line. The results of western blot analyses were consistent with these sensitivities. Next, similar experiments were also performed using the KYSE270 (L861Q) and KYSE 450 (S768I) cell lines, and their results were compatible with those of the transfectant Ba/F3 cell lines. Our findings suggest that NSCLC harboring the EGFR L861Q mutation might be sensitive to afatinib or osimertinib and that NSCLC harboring the EGFR S768I mutation might be sensitive to afatinib. Overall, afatinib might be the optimal EGFR‐TKI against these uncommon EGFR mutations. 相似文献
19.
20.
Massabeau C Sigal-Zafrani B Belin L Savignoni A Richardson M Kirova YM Cohen-Jonathan-Moyal E Mégnin-Chanet F Hall J Fourquet A 《Breast cancer research and treatment》2012,132(1):259-266
There is evidence that aspirin use reduces the risk of breast cancer. Increased mammographic density is known to be associated
with increased breast cancer risk. Little is known about the association between mammographic density and aspirin or other
non-steroidal anti-inflammatory drug (NSAID) use, but it is possible that the association between aspirin use and breast cancer
risk might be due to the effect of aspirin on mammographic density. Multiple linear regression was used to investigate the
association between measures of mammographic density and the use, frequency, and duration of aspirin and other NSAIDs such
as paracetamol (acetaminophen), arthritis medication, and other over-the-counter or doctor-prescribed pain medications in
3286 women from the Australian Mammographic Density Twins and Sisters Study and the Genes Behind Endometriosis Study. We found
no association between either dense area or percent dense area with any of the NSAIDs examined (all P > 0.06). If aspirin is reducing the breast cancer risk in women, it is likely doing so via a different pathway other than
mammographic density measures that predict breast cancer risk. 相似文献